UW-Madison School of Pharmacy

Navigation Options

head shot image

Weiping Tang, PhD

Director, Medicinal Chemistry Center

Organic Synthesis:

We are interested in developing novel reactions for the synthesis of carbo- and heterocycles that are present in diverse bioactive polycyclic natural products and pharmaceutical agents. Currently,  we are interesting in advancing glycoscience by streamlining the synthesis of carbohydrates through the development of novel technologies. We are also developing new methods for the synthesis of various heterocycles.

Medicinal Chemistry:

We are interested in optimizing the pharmacological properties of small molecules such as potency, selectivity, stability, and solubility for treating various human diseases. Currently, we are interested in developing small molecules that can selectively degrade disease-causing proteins. The small molecule protein degraders we developed can be used as probes to knock out proteins and therapeutics to treat human diseases.

Chemical Biology:

We are interested in dissecting the complex biological pathways by novel small molecule probes. We are currently developing small molecules that can selectively modulate protein stability and epigenetic markers.

Background: Dr. Weiping Tang joined the faculty of UW-Madison in 2007. His lab focuses on synthetic organic chemistry, medicinal chemistry, and chemical biology. Please visit his lab website (link on the left) for updated information.


  • BS 1997 Chemistry - Peking University
  • MS 1999 Chemistry - New York University
  • PhD 2005 Organic Chemistry - Stanford University
  • Postdoc 2007 Medicinal Chemistry, Chemical Biology and Drug Discovery - Harvard University

Awards and Honors:

  • Boehringer Ingelheim Predoctoral Fellowship (2002)
  • Amgen Predoctoral Fellowship (2003)
  • HHMI Postdoctoral Fellowship (2005-2007)
  • Thieme Synlett/Synthesis Journal Award (2010)
  • ACS Young Academic Investigator Symposium (2011)
  • Amgen Young Investigator Award (2011)
  • UW-Madison Vilas Mid-Career Award (2018)

Medicinal Chemistry II (PharmSci 532)

Natural Product Synthesis, Biosynthesis and Drug Discovery (PharmSci 786)

Highlighted Publications:
  • "Tumor Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction."  Jaskula-Sztul, R.; Eide, J.; Tesfazghi, S.; Dammalapati, A; Harrison, A.D.; Yu, X-M.; Scheinebeck, C.; Winston-McPherson, G.; Kupcho, K.R.; Robers, M.B.; Hundal, A.K.; Tang, W.;*Chen, H.* Mol. Cancer Therapy. 2015, 14, 499.
  • "Synthesis and Biological Evaluation of 2,3'-Diindolylmethanes as Agonists of Aryl Hydrocarbon Receptor."  Winston-McPherson, G.N.; Shu, D.; Tang, W.* Bioorg.Med.Chem.Lett. 2014, 24, 4023-4025.
  • "Stereoselective Preparation of Cyclobutanes with Four Different Substituents: Total Synthesis and Structural Revision of Pipercyclobutanamide A and Piperchabamide G." Liu, R.; Zhang, M.; Wyche, T. P.; Winston-McPherson, G. N.; Bugni, T. S.; Tang, W.* Angew. Chem. Int. Ed. 2012, 51, 7503-7506.
  • "Rhodium- and Platinum-catalyzed [4+3] Cycloaddition with Concomitant Indole Annulation: Synthesis of Cyclohepta[b]indoles" Shu, D.; Song, W.; Li, X.; Tang, W.* Angew. Chem. Int. Ed. 2013, 52, 3237-3240.
  • "Generation of Rhodium(I) Carbenes from Ynamides and Their Reactions with Alkynes and Alkenes." Liu, R.; Winston-McPherson, G. N.; Yang, Z.-Y.; Zhou, X.; Song, W.; Guzei, I. A.; Xu, X.;* Tang, W.* J. Am. Chem. Soc. 2013, 135, 8201–8204.
  • "Stereoselective Total Synthesis of Hainanolidol and Harringtonolide via Oxidopyrylium-Based [5+2] Cycloaddition" Zhang, M.; Liu, N.; Tang, W.* J. Am. Chem. Soc. 2013, 135, 12434-12438.
  • "Rhodium-Catalyzed Tandem Annulation and (5+1) Cycloaddition: 3-Hydroxy-1,4-Enyne as the 5-Carbon Component" Li, X.; Song, W.; Tang, W.* J. Am. Chem. Soc. 2013, 135, 16797-16800.